These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Biolo A; Fisch M; Balog J; Chao T; Schulze PC; Ooi H; Siwik D; Colucci WS Circ Heart Fail; 2010 Jan; 3(1):44-50. PubMed ID: 19850700 [TBL] [Abstract][Full Text] [Related]
4. Cluster analysis of extracellular matrix biomarkers predicts the development of impaired systolic function within 1 year of acute myocardial infarction. Brunton-O'Sullivan MM; Holley AS; Shi B; Harding SA; Larsen PD Heart Vessels; 2022 Dec; 37(12):2029-2038. PubMed ID: 35896723 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants. Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598 [TBL] [Abstract][Full Text] [Related]
6. Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure. Kato TS; Chokshi A; Singh P; Khawaja T; Iwata S; Homma S; Akashi H; Cheema F; Yang J; Takayama H; Naka Y; Farr M; Mancini D; Schulze PC J Heart Lung Transplant; 2012 Jan; 31(1):37-45. PubMed ID: 22071239 [TBL] [Abstract][Full Text] [Related]
7. Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure. Täger T; Wiebalck C; Fröhlich H; Corletto A; Katus HA; Frankenstein L Clin Res Cardiol; 2017 Dec; 106(12):974-985. PubMed ID: 28779229 [TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813 [TBL] [Abstract][Full Text] [Related]
9. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). Bonnema DD; Webb CS; Pennington WR; Stroud RE; Leonardi AE; Clark LL; McClure CD; Finklea L; Spinale FG; Zile MR J Card Fail; 2007 Sep; 13(7):530-40. PubMed ID: 17826643 [TBL] [Abstract][Full Text] [Related]
10. Role of TGF-beta1, extracellular matrix, and matrix metalloproteinase in the healing process of the pancreas after induction of acute necrotizing pancreatitis using arginine in rats. Kihara Y; Tashiro M; Nakamura H; Yamaguchi T; Yoshikawa H; Otsuki M Pancreas; 2001 Oct; 23(3):288-95. PubMed ID: 11590325 [TBL] [Abstract][Full Text] [Related]
11. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Tziakas DN; Chalikias GK; Hatzinikolaou EI; Stakos DA; Tentes IK; Kortsaris A; Hatseras DI; Kaski JC Am J Cardiol; 2005 Jul; 96(1):31-4. PubMed ID: 15979428 [TBL] [Abstract][Full Text] [Related]
12. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Bradham WS; Gunasinghe H; Holder JR; Multani M; Killip D; Anderson M; Meyer D; Spencer WH; Torre-Amione G; Spinale FG J Am Coll Cardiol; 2002 Dec; 40(12):2165-73. PubMed ID: 12505230 [TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Yilmaz Y; Eren F Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):43-46. PubMed ID: 30134384 [TBL] [Abstract][Full Text] [Related]
14. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Sundström J; Vasan RS Curr Opin Lipidol; 2006 Feb; 17(1):45-53. PubMed ID: 16407715 [TBL] [Abstract][Full Text] [Related]
15. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217 [TBL] [Abstract][Full Text] [Related]
16. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury. Yang K; Palm J; König J; Seeland U; Rosenkranz S; Feiden W; Rübe C; Rübe CE Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161 [TBL] [Abstract][Full Text] [Related]
17. Circulating matrix metalloproteinases and procollagen propeptides in inguinal hernia. Li J; Zhang X; Sun Q; Li W; Yu A; Fu H; Chen K Hernia; 2018 Jun; 22(3):541-547. PubMed ID: 29484522 [TBL] [Abstract][Full Text] [Related]
18. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Yang C; Qiao S; Song Y; Liu Y; Tang Y; Deng L; Yuan J; Hu F; Yang W Cardiovasc Pathol; 2019; 43():107150. PubMed ID: 31639652 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. Rubiś P; Wiśniowska-Śmiałek S; Dziewięcka E; Rudnicka-Sosin L; Kozanecki A; Podolec P Adv Med Sci; 2018 Mar; 63(1):160-166. PubMed ID: 29120858 [TBL] [Abstract][Full Text] [Related]